This molecular sub-classification could improve BC treatment techniques to a large extent, including guiding the delivery of targeted therapies such as hormone therapy (e.g., Toremifene) and HER2-targeted therapy (e.g., Pertuzumab) [4]. The gene discussed is ERBB2; the disease is breast cancer.